Tagged with Pricing

Servier The general manager of Servier Morocco reviews the situation of the market following the recent price cuts, how the local environment is changing with the rise of generics, and reveals his vision of creating a regional hub for Servier in Morocco. Today, Servier is number one in the Moroccan market for…

association Fatma Taman, Chair of ISPE and General Manager of PharmaVision, discusses the importance of proper education and training within the pharmaceutical industry to ensure the sector’s sustainable growth and development. Today we meet with you for the first time as the Chair of ISPE Turkey Affiliate; what have been your…

pricing The president and chairman of MC Pharma discusses the position of the pharmacy segment in the current Moroccan healthcare context.  Could you introduce MC Pharma to our international readers, and more especially describe the relationship that exists between MC Pharma and Cooper Pharma? MC Pharma was established in 2002 by…

Pfizer The country manager of Pfizer Morocco talks about the likelihood of Morocco becoming an African hub and why Pfizer is at the perfect size to play a key part in such a process, as well as how the country’s price decree hurt the multinational corporations.   Having been elected head of MIS…

generics At Valeant each region has a unique mix of prescription brands, branded generics and OTC products. The general manager for Mexico, Central America, the Caribbean and the Andean region discusses the company’s objectives for Spanish speaking Latin America and how it plans to leverage the recently acquired Bausch+Lomb business to…

MSD The managing director of MSD for Morocco, Tunisia, and French West Africa explains why the company has chosen Morocco as its hub for the region, discusses the difficulties associated with the government price cut and explains that pharma needs to focus on the local needs of the country.   Can…

pricing Daniel Varde, Deloitte’s top consultant for the healthcare and life sciences sector in Latin America, discusses the interaction of global, Latin American, and Argentinian healthcare trends, and strategic techniques for optimizing a pharmaceutical firm’s performance in Argentina’s price-controlled, high inflation market. With the current inflationary pressures to reduce costs, why…

Novo Nordisk The global COO of the multinational at the forefront of the fight against diabetes explains why the Algerian market is so strategically important and how the ‘made in Algeria’ brand would have real potential at the regional level if only the government would remove impediments to export. As COO of Novo…

doing business Insights from existing players on what to expect and how to succeed in Algeria today. “The key to being successful is to be direct and forthright with the Algerians themselves. Trust in them and they will certainly trust in you.” – Essam Farouk, CEO, El Kendi. “The pace of doing…

CNS Oh Pil-Soo, managing director of Lundbeck Korea, talks about the challenges of pricing and reimbursement in the CNS area and remaining committed to Korea in terms of clinical research.   What have been some of the biggest successes in the last three to four years for this affiliate? The greatest…

generics  Miriam Martinez, CEO of Laboratorios Duncan and VP of CAPGEN, discusses the challenges her company faces as a generic manufacturer in a branded generic market and their plans for growth in the future.   You are currently the Vice President of CAPGEN; could you please tell us a bit about…

innovation Brian Gladsden was appointed president of Novartis Korea in January 2014. He relates his previous experience to the market situation in Korea and highlights the importance of commitment to innovation and working in tandem with the local ecosystem to provide the best access to Korean patients.   You have had…